P3 Health Partners (PIII) Stock Price, News & Analysis

Company Overview

P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.

Key Stats

• Today's Range: $0.20 to $0.22
• 50-Day Range: $0.18 to $0.25
• 52-Week Range: $0.17 to $1.20
• Volume: 1.19 million shs
• Average Volume: 3.96 million shs
• Market Capitalization: $78.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.38
• Consensus Rating: Moderate Buy

P3 Health Partners Stock Analysis - MarketRank™

P3 Health Partners scored higher than 66% of companies evaluated by MarketBeat, and ranked 386th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

P3 Health Partners has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

P3 Health Partners has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for P3 Health Partners are expected to grow in the coming year, from ($0.67) to ($0.37) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of P3 Health Partners is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of P3 Health Partners is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

P3 Health Partners has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.44% of the float of P3 Health Partners has been sold short.

Short Interest Ratio / Days to Cover

P3 Health Partners has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in P3 Health Partners has recently decreased by 49.09%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

P3 Health Partners does not currently pay a dividend.

Dividend Growth

P3 Health Partners does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.44% of the float of P3 Health Partners has been sold short.

Short Interest Ratio / Days to Cover

P3 Health Partners has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in P3 Health Partners has recently decreased by 49.09%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.55

News Sentiment

P3 Health Partners has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for P3 Health Partners this week, compared to 1 article on an average week.

MarketBeat Follows

3 people have added P3 Health Partners to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, P3 Health Partners insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.86% of the stock of P3 Health Partners is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 7.75% of the stock of P3 Health Partners is held by institutions.

PIII Stock Analysis - Frequently Asked Questions

How have PIII shares performed this year?

P3 Health Partners' stock was trading at $0.2249 at the beginning of 2025. Since then, PIII stock has decreased by 2.2% and is now trading at $0.22.
View the best growth stocks for 2025 here.

Who are P3 Health Partners' major shareholders?

P3 Health Partners' top institutional investors include Alyeska Investment Group L.P. (3.32%), Corient Private Wealth LLC (0.35%), Trinity Financial Advisors LLC (0.29%) and Geode Capital Management LLC (0.26%). Insiders that own company stock include Pacific Founders Ugp Chicago, Pacific Founders Ugp I Chicago, Sherif Abdou and Atul Kavthekar.
View institutional ownership trends.

How do I buy shares of P3 Health Partners?

Shares of PIII stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of P3 Health Partners own?

Based on aggregate information from My MarketBeat watchlists, some other companies that P3 Health Partners investors own include Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), PayPal (PYPL), TriNet Group (TNET), Taiwan Semiconductor Manufacturing (TSM), XPeng (XPEV) and 3M (MMM).

Company Calendar

• Today: 2/20/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Health services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:PIII
• CUSIP: N/A
• CIK: 1832511
• Web: foresightacq.com
• Phone: 702-910-3950
• Fax: N/A
• Employees: 500
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $2.38
• High Stock Price Target: $4.50
• Low Stock Price Target: $0.25
• Potential Upside/Downside: +1,004.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-57,770,000.00
• Net Margins: -6.95%
• Pretax Margin: -16.87%
• Return on Equity: -71.31%
• Return on Assets: -11.93%

Debt

• Debt-to-Equity Ratio: 1.11
• Current Ratio: 0.53
• Quick Ratio: 0.53

Sales & Book Value

• Annual Sales: $1.27 billion
• Price / Sales: 0.06
• Cash Flow: $0.09 per share
• Price / Cash Flow: 2.46
• Book Value: $0.45 per share
• Price / Book: 0.48

Miscellaneous

• Outstanding Shares: 358,820,000
• Free Float: 294,735,000
• Market Cap: $77.15 million
• Optionable: Not Optionable
• Beta: 0.96